Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line irinotecan liposome + capecitabine + sintilimab with or without bevacizumab in RAS-mutant MSS metastatic colorectal cancer
ChiCTR2500097870Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome, capecitabine, sintilimab and bevacizumab in colorectal cancer (CRC), sponsored by Sichuan Cancer Hospital. Primary endpoints: Objective response rate and Adverse events. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
irinotecan liposomecapecitabinesintilimabbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2500097870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097870.